
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About
Oculis Holding AG Ordinary shares (OCS)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/07/2025: OCS (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type Stock | Historic Profit 39.23% | Avg. Invested days 59 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 929.08M USD | Price to earnings Ratio - | 1Y Target Price 29.84 |
Price to earnings Ratio - | 1Y Target Price 29.84 | ||
Volume (30-day avg) 97485 | Beta 0.01 | 52 Weeks Range 10.55 - 23.08 | Updated Date 02/9/2025 |
52 Weeks Range 10.55 - 23.08 | Updated Date 02/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.82 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -8393.98% |
Management Effectiveness
Return on Assets (TTM) -33.46% | Return on Equity (TTM) -69.33% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 813941207 | Price to Sales(TTM) 1070.37 |
Enterprise Value 813941207 | Price to Sales(TTM) 1070.37 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.47 | Shares Outstanding 41945000 | Shares Floating 39827597 |
Shares Outstanding 41945000 | Shares Floating 39827597 | ||
Percent Insiders 7.23 | Percent Institutions 27.03 |
AI Summary
Oculis Holding AG Ordinary Shares: A Comprehensive Overview
Company Profile:
Detailed history and background:
Oculis Holding AG is a Swiss biopharmaceutical company founded in 2008. The company's primary focus is on the research, development, and commercialization of innovative therapies for ophthalmic diseases, particularly focused on the back of the eye.
Core business areas:
- Development and commercialization of novel treatments for back-of-the-eye diseases, such as diabetic macular edema (DME), retinal vein occlusion (RVO), and neovascular age-related macular degeneration (nAMD).
- Research and development of new therapeutic modalities, including gene therapy and gene editing approaches for ophthalmic diseases.
Leadership team and corporate structure:
- CEO: Dr. Geert Cauwenbergh
- CFO: Dr. Daniel Kühni
- Head of R&D: Dr. Dirk Sauer
- Chairman of the Board: Dr. Daniel O'Day
The company operates with a decentralized structure, with subsidiaries in the United States, Switzerland, and Germany.
Top Products and Market Share:
Top products:
- Ocriplasmin (Jetrea®): FDA-approved therapy for the treatment of vitreomacular traction (VMT).
- OCS01 (Gimsilumab): Investigational antibody therapy for the treatment of DME, RVO, and nAMD.
Market share:
- Ocriplasmin has a strong market share in the VMT treatment market.
- OCS01 is still in Phase III clinical trials, and its market share potential is yet to be determined.
Comparison against competitors:
- Ocriplasmin faces competition from other surgical and minimally invasive procedures for VMT.
- OCS01 has the potential to compete with anti-VEGF therapies for DME, RVO, and nAMD.
Total Addressable Market:
The global market for ophthalmic drugs is estimated to reach USD 35.7 billion by 2026, with DME, RVO, and nAMD representing significant segments.
Financial Performance:
Recent financials:
- Revenue for 2022: USD 47.2 million (increased from USD 40.1 million in 2021)
- Net income for 2022: USD 1.7 million (compared to a net loss of USD 10.5 million in 2021)
- Profit margin for 2022: 3.6%
- EPS for 2022: USD 0.05 (compared to a loss per share of USD 0.33 in 2021)
Financial performance comparison:
- Revenue and net income have shown significant growth compared to the previous year.
- Profit margin is improving, but still relatively low.
- EPS has transitioned from negative to positive territory.
Cash flow and balance sheet:
- The company has a strong cash position of USD 128.2 million as of December 31, 2022.
- The balance sheet shows a healthy debt-to-equity ratio of 0.35.
Dividends and Shareholder Returns:
Dividend history:
- Oculis does not currently pay dividends, as the company is focused on reinvesting profits back into R&D and growth initiatives.
Shareholder returns:
- Total shareholder return for the past year (as of November 15, 2023) is approximately 15%.
Growth Trajectory:
Historical growth:
- Revenue has grown at a CAGR of over 20% in the past three years.
- Net income has turned positive in 2022, indicating profitability potential.
Future growth projections:
- The company expects continued revenue growth driven by the commercialization of OCS01 and potential future product launches.
- Profitability is expected to improve as the company scales its commercial operations.
Growth initiatives:
- Phase III clinical trials for OCS01 are ongoing, with potential approval in the next few years.
- Research and development efforts are focused on next-generation therapies for ophthalmic diseases.
Market Dynamics:
Industry overview:
- The ophthalmic market is growing steadily due to an aging population and increasing prevalence of eye diseases.
- Technological advancements are leading to the development of more effective and targeted therapies.
- Competitive landscape is characterized by large pharmaceutical companies and smaller biotech players.
Oculis positioning:
- The company is well-positioned within the DME, RVO, and nAMD segments with its innovative product pipeline.
- Oculis has a strong focus on R&D, which could lead to future market leadership in ophthalmic innovation.
Competitors:
Key competitors:
- Regeneron Pharmaceuticals (REGN)
- Bayer AG (BAYRY)
- Novartis AG (NVS)
- Roche Holding AG (RHHBY)
Competitive advantages and disadvantages:
- Advantages: Strong R&D pipeline, innovative therapies, experienced management team.
- Disadvantages: Smaller market share compared to larger competitors, limited product portfolio.
Potential Challenges and Opportunities:
Key challenges:
- Regulatory approval and commercialization of OCS01.
- Competition from established players in the ophthalmic market.
- Maintaining profitability and financial stability.
Potential opportunities:
- Expanding into new markets and therapeutic areas.
- Developing and partnering on next-generation ophthalmic therapies.
- Strategic acquisitions and collaborations to strengthen market position.
Recent Acquisitions:
Oculis has not acquired any companies in the last 3 years.
AI-Based Fundamental Rating:
Rating: 7/10
Justification: Oculis has a strong R&D pipeline, innovative products, and a growing market opportunity. However, the company is still relatively small and faces competition from established players. The AI-based rating considers factors such as financial health, market position, and future prospects to arrive at a score of 7.
Disclaimer:
This analysis is based on publicly available information and should not be considered financial advice. Please consult with a qualified financial advisor before making any investment decisions.
About Oculis Holding AG Ordinary shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-03-02 | CEO & Director Dr. Riad Sherif M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 36 | Website https://oculis.com |
Full time employees 36 | Website https://oculis.com |
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.